688235 百济神州
已收盘 05-15 15:00:01
资讯
新帖
简况
百济神州(06160)：百悦达®获美国FDA批准成为美国首款且目前唯一治疗复发╱难治套细胞淋巴瘤的BCL2抑制剂
智通财经 · 05-14
百济神州(06160)：百悦达®获美国FDA批准成为美国首款且目前唯一治疗复发╱难治套细胞淋巴瘤的BCL2抑制剂
百济神州Beqalzi™ (Sonrotoclax)获美国FDA批准，成为首个且唯一用于R/R套细胞淋巴瘤的Bcl2抑制剂
美股速递 · 05-14
百济神州Beqalzi™ (Sonrotoclax)获美国FDA批准，成为首个且唯一用于R/R套细胞淋巴瘤的Bcl2抑制剂
科技仍是主战场？知名基金经理打出什么“隐形牌”
第一财经 · 05-13
科技仍是主战场？知名基金经理打出什么“隐形牌”
百济神州(06160)：授出受限制股份单位
智通财经 · 05-13
百济神州(06160)：授出受限制股份单位
中邮证券：给予百济神州买入评级
证券之星 · 05-13
中邮证券：给予百济神州买入评级
百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%
证券之星 · 05-12
百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%
百济神州一季度净利润超16亿元；今年医保谈判工作启动
21世纪经济报道 · 05-11
百济神州一季度净利润超16亿元；今年医保谈判工作启动
百济神州(06160)发布第一季度业绩 归母净利润16.08亿元 同比扭亏为盈
智通财经网 · 05-11
百济神州(06160)发布第一季度业绩 归母净利润16.08亿元 同比扭亏为盈
5月11日百济神州涨5.89%，万家行业优选LOF基金重仓该股
证券之星 · 05-11
5月11日百济神州涨5.89%，万家行业优选LOF基金重仓该股
百济神州涨5.89%，浦银国际证券二个月前给出“买入”评级，目前股价已超目标价
证券之星 · 05-11
百济神州涨5.89%，浦银国际证券二个月前给出“买入”评级，目前股价已超目标价
【机构调研记录】恒生前海基金调研百济神州
证券之星 · 05-11
【机构调研记录】恒生前海基金调研百济神州
每周股票复盘：百济神州（688235）上调2026年收入指引至452亿元
证券之星 · 05-10
每周股票复盘：百济神州（688235）上调2026年收入指引至452亿元
百济神州（688235）披露美股S-3注册申请用于特定股东转售普通股，5月8日股价下跌2.71%
证券之星 · 05-08
百济神州（688235）披露美股S-3注册申请用于特定股东转售普通股，5月8日股价下跌2.71%
【券商聚焦】招银国际维持百济神州(ONC/06160)“买入”评级 指近期临床数据读出将验证创新管线价值
金吾财讯 · 05-08
【券商聚焦】招银国际维持百济神州(ONC/06160)“买入”评级 指近期临床数据读出将验证创新管线价值
中金：维持百济神州(06160)跑赢行业评级 目标价250港元
智通财经 · 05-08
中金：维持百济神州(06160)跑赢行业评级 目标价250港元
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
赛柏蓝 · 05-07
多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…
百济神州：5月6日召开业绩说明会，AJ Asset Management、Everbright PGIM Fund等多家机构参与
证券之星 · 05-07
百济神州：5月6日召开业绩说明会，AJ Asset Management、Everbright PGIM Fund等多家机构参与
港股异动 | 百济神州(06160)绩后高开逾4% 一季度净利同比增长178.02倍 百悦泽全球销售额11亿美元
智通财经 · 05-07
港股异动 | 百济神州(06160)绩后高开逾4% 一季度净利同比增长178.02倍 百悦泽全球销售额11亿美元
港股开盘强势 恒指高开1.21% 快手-W(01024)涨5.20%
金吾财讯 · 05-07
港股开盘强势 恒指高开1.21% 快手-W(01024)涨5.20%
智通港股早知道 | 碳酸锂现货价格大幅上行 百济神州(06160)一季度净利润同比增长178.02倍
智通财经 · 05-07
智通港股早知道 | 碳酸锂现货价格大幅上行 百济神州(06160)一季度净利润同比增长178.02倍
暂无数据
公司概况
公司名称：
百济神州有限公司
所属行业：
医药制造业
上市日期：
2021-12-15
主营业务：
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。
发行价格：
192.60
{"stockData":{"symbol":"688235","market":"SH","secType":"STK","nameCN":"百济神州","latestPrice":252.02,"timestamp":1778828401000,"preClose":249.7,"halted":0,"volume":3655977,"delay":0,"changeRate":0.0093,"floatShares":114999999,"shares":1542000000,"eps":2.0518,"marketStatus":"已收盘","change":2.32,"latestTime":"05-15 15:00:01","open":249.71,"high":254.63,"low":247.41,"amount":917000000,"amplitude":0.0289,"askPrice":252.02,"askSize":106,"bidPrice":252,"bidSize":18,"shortable":0,"etf":0,"ttmEps":2.0518,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1779067800000},"marketStatusCode":5,"adr":0,"adjPreClose":249.7,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778808600000,1778815800000],[1778821200000,1778828400000]],"highLimit":274.67,"lowLimit":224.73,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1541583805,"isCdr":false,"pbRate":11.76,"roa":"--","peRate":122.828736,"roe":"5.05%","epsLYR":1.03,"committee":-0.47486,"marketValue":388510000000,"turnoverRate":0.0318,"status":0,"afterMarket":{"amount":0,"volume":0,"close":252.02,"buyVolume":200,"sellVolume":0,"time":1778830437559,"indexStatus":"已收盘 05-15 15:30:00","preClose":249.7},"hkstockBrief":{"symbol":"06160","market":"HK","secType":"STK","nameCN":"百济神州","latestPrice":179.3,"timestamp":1778832545007,"preClose":184.7,"halted":0,"volume":4215644,"delay":0,"premium":"-38.13"},"floatMarketCap":28996000000},"requestUrl":"/m/hq/s/688235/tweets","defaultTab":"tweets","newsList":[{"id":"2635936752","title":"百济神州(06160)：百悦达®获美国FDA批准成为美国首款且目前唯一治疗复发╱难治套细胞淋巴瘤的BCL2抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=2635936752","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635936752?lang=zh_cn&edition=full","pubTime":"2026-05-14 07:47","pubTimestamp":1778716032,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州 发布公告，公司于2026年5月13日宣布百悦达获得美国食品药品监督管理局加速批准，用于治疗既往接受过至少两线系统治疗的复发或难治性(R/R)套细胞淋巴瘤成人患者。索托克拉是一款在BCL2靶点研发中具有基石性潜力的新一代BCL2抑制剂，其研发设计以增强BCL2抑制剂作用为目标，在分子效力和选择性方面进行了优化，且其药理学特性也有望改善用药的有效性、耐受性和便利性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","LABU","BK1161","ONC","BK0239","LU1770034418.SGD","LU0588546209.SGD","LU1251922891.USD","06160","LU1969619763.USD","BK1588","LU1719994722.HKD","BK4588","BK1500","BK1583","BK4139","LU1303224171.USD","688235","LU0307460666.USD","LU2328871848.SGD","BK4526"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1113457800","title":"百济神州Beqalzi™ (Sonrotoclax)获美国FDA批准，成为首个且唯一用于R/R套细胞淋巴瘤的Bcl2抑制剂","url":"https://stock-news.laohu8.com/highlight/detail?id=1113457800","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113457800?lang=zh_cn&edition=full","pubTime":"2026-05-14 01:28","pubTimestamp":1778693292,"startTime":"0","endTime":"0","summary":"百济神州旗下药物Beqalzi™ (Sonrotoclax)已获得美国食品药品监督管理局的批准，成为首个且唯一获批用于治疗复发或难治性套细胞淋巴瘤的Bcl2抑制剂。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635878967","title":"科技仍是主战场？知名基金经理打出什么“隐形牌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2635878967","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635878967?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:36","pubTimestamp":1778675760,"startTime":"0","endTime":"0","summary":" 当市场还在复盘一季报时，部分机构投资者的“隐形棋”已经落子。 随着多家上市公司因股份回购等事项更新股东名单，一批知名基金经理的“隐秘”调仓路径曝光。 与此同时，机构调研热度持续升温，科技板块仍是资金关注的核心腹地。 日前，力源信息因股份回购事宜更新前十名股东及前十名无限售条件股东持股情况。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/roll/2026-05-13/doc-inhxufvi4481411.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-05-13/doc-inhxufvi4481411.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0148","LU2580892789.USD","LU0417516902.SGD","LU2580892862.HKD","IE00BYTNYN87.SGD","301498","LU0348735423.USD","SG9999011746.SGD","LU2778985437.USD","LU2476274308.USD","LU1720050803.USD","LU0561508036.HKD","LU1303224171.USD","BK0167","LU2213484517.USD","002126","IE00B12V2V27.USD","LU1770034418.SGD","LU2495084118.USD","BK0132","BK0161","LU1934453819.USD","LU0417516738.SGD","LU0871576103.HKD","688235","LU0540923850.HKD","300502","BK0028","LU0531971595.HKD","002705","300184","LU0164939612.USD","LU2476274720.SGD","LU0039217434.USD","LU0634319403.HKD","LU1781817850.SGD","LU1997245177.USD","LU1251922891.USD","LU0348825331.USD","LU1580142542.USD","300308","LU0164865239.USD","BK0239","BK0214","BK0175","LU1997244956.HKD","LU2289578879.USD","LU0082770016.USD","BK0109","HK0000306685.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635202523","title":"百济神州(06160)：授出受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2635202523","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635202523?lang=zh_cn&edition=full","pubTime":"2026-05-13 17:04","pubTimestamp":1778663056,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布公告，于2026年5月8日，董事会薪酬委员会根据2016期权及激励计划的条款向201名承授人授出涉及合共25,436股美国存托股份的受限制股份单位。该等受限制股份单位相当于330,668股股份，约占本公告之日公司发行股份总数的0.02%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1441212.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0588546209.SGD","BK4526","ONC","LU1303224171.USD","BK4588","BK1161","LU2328871848.SGD","LU1770034418.SGD","688235","BK1588","LU0307460666.USD","06160","BK1500","BK0239","LU1719994722.HKD","LU1251922891.USD","LU1969619763.USD","BK1583","BK4139","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635205859","title":"中邮证券：给予百济神州买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2635205859","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635205859?lang=zh_cn&edition=full","pubTime":"2026-05-13 15:05","pubTimestamp":1778655925,"startTime":"0","endTime":"0","summary":"中邮证券有限责任公司盛丽华,陈灿近期对百济神州进行研究并发布了研究报告《泽布替尼同比维持高增，全年业绩指引上调》，给予百济神州买入评级。公司为创新药出海龙头企业，全球商业化能力突出、在研管线即将进入收获期，维持“买入”评级。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为321.19。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300021645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688235","161027","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634291209","title":"百济神州(688235)3月31日股东户数3.52万户，较上期增加6.53%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634291209","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634291209?lang=zh_cn&edition=full","pubTime":"2026-05-12 17:18","pubTimestamp":1778577534,"startTime":"0","endTime":"0","summary":"证券之星消息，近日百济神州披露，截至2026年3月31日公司股东户数为3.52万户，较12月31日增加2161.0户，增幅为6.53%。在化学制药行业个股中，百济神州股东户数低于行业平均水平，截至3月31日，化学制药行业平均股东户数为3.58万户。从股价来看，2025年12月31日至2026年3月31日，百济神州区间跌幅为13.03%，在此期间股东户数增加2161.0户，增幅为6.53%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051200029275.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1588","LU2328871848.SGD","BK1500","LU1719994722.HKD","LU0307460666.USD","BK1161","LU0588546209.SGD","LU1770034418.SGD","LU1251922891.USD","06160","688235","BK0239","BK1583","LU1969619763.USD","LU1303224171.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634228933","title":"百济神州一季度净利润超16亿元；今年医保谈判工作启动","url":"https://stock-news.laohu8.com/highlight/detail?id=2634228933","media":"21世纪经济报道","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634228933?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:04","pubTimestamp":1778501046,"startTime":"0","endTime":"0","summary":"政策动向今年医保谈判工作启动近日，国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》，并向社会公开征求意见。21点评：根据《征求意见稿》，今年的工作程序仍分为准备、申报、评审、谈判、公布结果5个阶段。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605113733316580.html","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605113733316580.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688235","ONC","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634288993","title":"百济神州(06160)发布第一季度业绩 归母净利润16.08亿元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2634288993","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634288993?lang=zh_cn&edition=full","pubTime":"2026-05-11 18:57","pubTimestamp":1778497043,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百济神州(06160)发布2026年第一季度业绩，该集团取得营业收入105.44亿元，同比增长31.0%;归属于上市公司股东的净利润16.08亿元，同比扭亏为盈;基本每股收益1.11元。更多港股重磅资讯，下载智通财经app更多港股及海外理财资讯，请点击www.zhitongcaijing.com（搜索“智通财经”）；欲加入智通港股投资群，请加智通客服微信(ztcjkf)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440306.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["06160","ONC","688235"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634409612","title":"5月11日百济神州涨5.89%，万家行业优选LOF基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2634409612","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634409612?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:30","pubTimestamp":1778488246,"startTime":"0","endTime":"0","summary":"证券之星消息，5月11日百济神州涨5.89%，收盘报262.08元，换手率5.41%，成交量6.23万手，成交额15.82亿元。重仓百济神州的前十大公募基金请见下表：该股最近90天内共有3家机构给出评级，买入评级3家；过去90天内机构目标均价为330.49。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共107家，其中持有数量最多的公募基金为万家基金的万家行业优选LOF。万家行业优选LOF目前规模为58.28亿元，最新净值1.5479，较上一交易日下跌1.13%，近一年上涨31.77%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021927.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1500","LU0588546209.SGD","LU1303224171.USD","LU1719994722.HKD","LU1969619763.USD","688235","160916","BK0239","BK1583","LU0307460666.USD","LU2328871848.SGD","LU1251922891.USD","BK1588","LU1770034418.SGD","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634625409","title":"百济神州涨5.89%，浦银国际证券二个月前给出“买入”评级，目前股价已超目标价","url":"https://stock-news.laohu8.com/highlight/detail?id=2634625409","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634625409?lang=zh_cn&edition=full","pubTime":"2026-05-11 16:30","pubTimestamp":1778488238,"startTime":"0","endTime":"0","summary":"今日百济神州涨5.89%，收盘报262.08元。2026年3月9日，浦银国际证券研究员阳景,胡泽宇发布了对百济神州的研报《四季度收入符合预期，2026年催化剂丰富》，该研报对百济神州给出“买入”评级，认为其目标价为236.0元，现价已超分析师预估，涨幅达到11.05%。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为9.25%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为中信证券的甘坛焕。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100021923.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","688235","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634222854","title":"【机构调研记录】恒生前海基金调研百济神州","url":"https://stock-news.laohu8.com/highlight/detail?id=2634222854","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634222854?lang=zh_cn&edition=full","pubTime":"2026-05-11 08:03","pubTimestamp":1778457786,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及5月8日披露的机构调研信息，恒生前海基金近期对1家上市公司进行了调研，相关名单如下：1）百济神州 调研纪要：百悦泽?恒生前海基金成立于2016年，截至目前，资产管理规模236.06亿元，排名118/212；资产管理规模236.03亿元，排名99/212；管理公募基金数69只，排名91/212；旗下公募基金经理8人，排名120/212。旗下最近一年表现最佳的公募基金产品为恒生前海高端制造混合A，最新单位净值为1.6，近一年增长141.07%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051100002319.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","06160","BK1500","LU0307460666.USD","LU1251922891.USD","LU1770034418.SGD","688235","LU2328871848.SGD","BK1583","BK1588","LU0588546209.SGD","LU1719994722.HKD","BK1161","LU1969619763.USD","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634118094","title":"每周股票复盘：百济神州（688235）上调2026年收入指引至452亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634118094","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634118094?lang=zh_cn&edition=full","pubTime":"2026-05-10 01:17","pubTimestamp":1778347029,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，百济神州报收于247.5元，较上周的234.8元上涨5.41%。公司公告汇总百济神州有限公司自愿披露关于2026年度经营业绩预测调整的公告，将2026年营业收入指引由人民币436亿元至450亿元上调至436亿元至452亿元。百济神州有限公司发布2026年第一季度主要财务数据公告，营业总收入为105.44亿元，同比增长31.0%；产品收入为103.21亿元，同比增长29.3%。港股公告显示，百济神州2026年第一季度未经审核全球总收入达15.13亿美元，同比增长35%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","LU1969619763.USD","BK1583","BK1588","LU1303224171.USD","06160","LU0588546209.SGD","LU1770034418.SGD","LU1251922891.USD","LU1719994722.HKD","688235","BK0239","LU2328871848.SGD","BK1500","LU0307460666.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633559439","title":"百济神州（688235）披露美股S-3注册申请用于特定股东转售普通股，5月8日股价下跌2.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633559439","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633559439?lang=zh_cn&edition=full","pubTime":"2026-05-08 17:16","pubTimestamp":1778231783,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，百济神州报收于247.5元，较前一交易日下跌2.71%，最新总市值为3815.01亿元。该股当日开盘254.4元，最高257.4元，最低247.0元，成交额达10.16亿元，换手率为3.53%。近日，百济神州有限公司提交S-3注册申请表，用于注册398,880,905股普通股，由特定出售股东进行转售。公司不会从本次发售中获得资金，仅承担注册及发行相关费用。注册申请于2026年5月6日提交，有效期至2026年5月9日到期的前次注册表终止。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050800030513.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","06160","BK1583","LU1770034418.SGD","LU0307460666.USD","BK1500","LU0588546209.SGD","LU2328871848.SGD","688235","BK0239","LU1251922891.USD","LU1719994722.HKD","BK1588","BK1161","LU1969619763.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633486147","title":"【券商聚焦】招银国际维持百济神州(ONC/06160)“买入”评级 指近期临床数据读出将验证创新管线价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2633486147","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633486147?lang=zh_cn&edition=full","pubTime":"2026-05-08 13:17","pubTimestamp":1778217451,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招银国际研报指，百济神州 1Q26业绩强劲，盈利改善，管理层上调全年指引。此外，近期多项临床数据的读出将为公司估值的提升提供强有力的催化剂。此外，BTK CDAC的美国NDA预计将于下半年递交。实体瘤催化剂丰富： 在即将到来的ASCO年会上，公司将公布CDK4抑制剂、GPC3/4-1BB双抗及B7-H4 ADC的临床数据。CDK4抑制剂已经进入一线乳腺癌三期临床。GPC3/4-1BB双抗也已经进入后线肝癌注册临床阶段。维持“买入”评级，维持基于DCF模型的目标价392.43美元不变。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980931","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","688235","06160"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633107844","title":"中金：维持百济神州(06160)跑赢行业评级 目标价250港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633107844","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633107844?lang=zh_cn&edition=full","pubTime":"2026-05-08 09:37","pubTimestamp":1778204248,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中金发布研报称，综合考虑百济神州费用控制，维持2026年收入预测不变，上调盈利预测7.1%至6.5亿美元，并维持2027年盈利预测不变。该行维持跑赢行业评级，基于DCF模型，该行维持A/H/US股目标价320元/250港币/420美元。1Q26替雷利珠单抗全球销售额2.06亿美元，YoY +20%。GAAP净利润达到2.27亿美元，单季度盈利首次超过2亿美元，超过该行预期。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439361.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","688235","EWH","ONC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633794147","title":"多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…","url":"https://stock-news.laohu8.com/highlight/detail?id=2633794147","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633794147?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:53","pubTimestamp":1778154780,"startTime":"0","endTime":"0","summary":"01本土制药企业与Biotech迎高管变动恒瑞医药、再鼎医药、百济神州、和铂医药、复星医药映射出了中国创新药发展过程中企业所处的不同阶段。4月16日，恒瑞医药发布公告，正式完成新一届董事会和管理层聘任。复星医药4月2日，复星医药发布首席财务官变更公告，因工作安排调整，陈战宇辞去首席财务官职务。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-07/doc-inhxatff4708181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IE00BLSP4239.USD","BK4588","02196","PFE","02142","IE000M9KFDE8.USD","BK4599","SG9999011175.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU0306806265.USD","AZNH","LU1894683264.USD","LU2417539215.USD","BK4534","LU2237443895.HKD","LU2462157665.USD","LU1829250122.USD","LU0225284248.USD","BK4550","LU2237443622.USD","LU0109394709.USD","ONC","BK4568","LU1066051498.USD","LU2456880835.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","LU0234572021.USD","LU2237443382.USD","LU0289739699.SGD","LU0321505439.SGD","688235","LU0321505868.SGD","LU0456855351.SGD","LU1883839398.USD","LU1894683348.USD","LU2236285917.USD","LU2237443978.SGD","600276","IE00B3T34201.USD","LU0306807586.USD","BK4533","LU0889565916.HKD","SG9999001176.USD","SG9999003800.SGD","LU0868494617.USD","LU2237443549.SGD","SG9999002232.USD","SG9999002224.SGD","BK4585","LU0985481810.HKD","600196","SG9999001176.SGD","LU0170899867.USD","LU1023059063.AUD","LU0122379950.USD","IE00B19Z3581.USD","IE00BLSP4452.SGD","LU0320765992.SGD","BK4581","IE0002270589.USD","01276","LU1066053197.SGD","AZN","06160","LU0225771236.USD","SG9999013999.USD","BK4592","BK4007","LU2237443465.HKD","LU1057294990.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633149675","title":"百济神州：5月6日召开业绩说明会，AJ Asset Management、Everbright PGIM Fund等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2633149675","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633149675?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:30","pubTimestamp":1778153458,"startTime":"0","endTime":"0","summary":"一季度产生了约2,000万美元的非经常性净额，仅发生在一季度，公司预计其影响将贯穿全年。整体业务布局态势良好。公司将于今年SCO年会公布1期临床数据，相关摘要即将发布。在联合替雷利珠单抗 + 贝伐珠单抗一线治疗HCC的临床试验中，目前已入组超 40例患者。于今年1月在中国获批，获批后仅8天便正式商业化上市。年初至今，国内已有超300家医院开始使用该药物开展患者治疗。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700035908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["LU1303224171.USD","BK1500","BK1583","BK1161","LU0588546209.SGD","LU1251922891.USD","06160","688235","LU1969619763.USD","LU0307460666.USD","LU2328871848.SGD","BK0239","BK1588","LU1719994722.HKD","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633416218","title":"港股异动 | 百济神州(06160)绩后高开逾4% 一季度净利同比增长178.02倍 百悦泽全球销售额11亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633416218","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633416218?lang=zh_cn&edition=full","pubTime":"2026-05-07 09:25","pubTimestamp":1778117150,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百济神州绩后高开逾4%，截至发稿，涨4.07%，报189.4港元，成交额4130.72万港元。消息面上，5月6日，百济神州公布2026年第一季度业绩，全球总收入达约15.13亿美元，同比增长35%。经调整经营利润约4.14亿美元，同比增长197%；经调整净利润约3.75亿美元，同比增长175%；净利润约2.27亿美元，同比增长178.02倍；自由现金流约1.61亿美元，同比增长14.03倍。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"b1300d74fa2f8add3d36093521acc10f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438856.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1251922891.USD","BK1583","BK4526","LU1969619763.USD","LU1719994722.HKD","LU1303224171.USD","BK4139","BK0239","BK1588","06160","LU0307460666.USD","BK4585","BK1500","VXUS","LU0588546209.SGD","BK1161","BK4588","LU2328871848.SGD","688235","ONC","LU1770034418.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633162625","title":"港股开盘强势 恒指高开1.21% 快手-W(01024)涨5.20%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633162625","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633162625?lang=zh_cn&edition=full","pubTime":"2026-05-07 09:24","pubTimestamp":1778117045,"startTime":"0","endTime":"0","summary":"金吾财讯 | 美伊将达成结束战争协议，刺激大市气氛向上，隔晚美股强势带动港股情绪，恒指高开1.21%，国企指数高开1.3%，恒生科技指数高开2.41%。期内，经调整净利润3.75亿美元，按年增加175%。东方证券高开1.87%，公司宣布，向卖方收购上海证券合计100%股权。该公司已向上海证交所申请A股5月7日复牌。内地股市假后复市，大市走势向好，沪综指高开高走，收市上升1.2%，沪深两市成交额超过三万亿元水平。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YWY0NWM4YTUxZGFlZmZjNmE5MDYxNjI4NjU1Mjc3NzM1Mzg=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"fbe774582fff1943fbc8392a6b2fba8b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1980764","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2097828805.USD","00883","LU0862451837.USD","LU1808992512.USD","SGXZ86797644.SGD","IE00B19Z5X02.USD","01378","00857","SG9999014674.SGD","BK1610","LU1251922891.USD","LU0348783233.USD","BK1615","CSUAY","SGXZ62798434.SGD","LU0405327494.USD","LU1115378108.SGD","LU2293587155.HKD","LU0862451753.SGD","LU1023057109.AUD","BIDU","LU1785774172.SGD","LU1497734951.SGD","LU0051755006.USD","601857","LU0211977185.USD","000333","BABA","LU1188198961.HKD","LU1522347837.USD","LU1282651048.USD","LU0675040207.SGD","LU1719994722.HKD","LU0320764599.SGD","LU2399975544.HKD","LU0314109678.HKD","LU1282651121.HKD","02833","LU0463099449.HKD","BK4588","LU1634259391.SGD","BK1095","LU0611395673.USD","IE00BQJZWZ67.USD","LU1770034418.SGD","LU0634319403.HKD","09988","LU0210526637.USD","LU0540923850.HKD","LU0173614495.USD","LU0588546209.SGD","BK1147","LU0359201885.HKD","LU0572944931.SGD","LU2328871848.SGD","BK1608","XYIGY","03958","603993","LU0359201612.USD","01088","LU0307460666.USD","LU2097828474.EUR","00300","BK1575","LU1961090484.USD","LU0348767384.USD","LU0348784397.USD","LU2097828557.USD","LU0561508036.HKD","LU0293314216.USD","SG9999001093.SGD","LU0052750758.USD","LU0593848301.USD","600938","BK1564","LU1969619763.USD","LU1303224171.USD","LU1720050803.USD","LU0640798160.USD","ONC","BK1528","LU1497733557.USD","CJEWY","LU0140636845.USD","LU0417516738.SGD","IE00BWDBJ730.SGD","600958","688235","LU0348783662.USD","LU2097828631.EUR","SG9999006597.SGD","601088","LU0072462343.USD","SG9999004220.SGD","LU0326950275.SGD","LU0417516571.SGD","LU0417516902.SGD","09961","LU0181495838.USD","LU0348805143.USD","LU1634259557.SGD","LU0441854154.USD","HHImain","513600","BK4585","MCHmain","LU2039709279.SGD","HSTECH","LU0244354667.USD","01929","LU1224444064.USD","LU1048588211.SGD","BK1591","LU0972618739.USD","LU0348766576.USD","LU0456827905.SGD","LU0348825331.USD","01024","03993","81024","LU1328277881.USD","LU0405327148.USD","06160","BK1521","LU0287142896.SGD","LU0348827113.USD","LU0348735423.USD","LU0327786744.USD","00868","LU2097828714.EUR","LU0359202008.SGD","LU0890818403.SGD","LU1794554557.SGD","LU0469268626.HKD","09888","TCOM","BK1226","LU0708995583.HKD","SG9999003461.SGD","HSI","LU1813983027.USD","LU1497733631.SGD","BK1590","LU1831875114.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633166139","title":"智通港股早知道 | 碳酸锂现货价格大幅上行 百济神州(06160)一季度净利润同比增长178.02倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2633166139","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633166139?lang=zh_cn&edition=full","pubTime":"2026-05-07 07:09","pubTimestamp":1778108970,"startTime":"0","endTime":"0","summary":"前十款智能手机合计贡献了全球 25% 的出货量，创下历年第一季度最高集中度。百济神州：一季度净利润同比增长178.02倍至2.27亿美元智通财经APP讯，百济神州公布2026年第一季度业绩，全球总收入达约15.13亿美元，同比增长35%。经调整经营利润约4.14亿美元，同比增长197%；经调整净利润约3.75亿美元，同比增长175%；净利润约2.27亿美元，同比增长178.02倍；自由现金流约1.61亿美元，同比增长14.03倍。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"b1300d74fa2f8add3d36093521acc10f","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438814.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06160","ONC","688235","VXUS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1779044099754,"stockEarnings":[{"period":"1week","weight":0.0183},{"period":"1month","weight":-0.0094},{"period":"3month","weight":-0.0987},{"period":"6month","weight":-0.1566},{"period":"1year","weight":0.1257},{"period":"ytd","weight":-0.0617}],"compareEarnings":[{"period":"1week","weight":-0.0107},{"period":"1month","weight":0.0269},{"period":"3month","weight":0.0131},{"period":"6month","weight":0.0363},{"period":"1year","weight":0.2232},{"period":"ytd","weight":0.042}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百济神州有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"35235人(较上一季度增加6.53%)","perCapita":"3265股","listingDate":"2021-12-15","address":"c/oBeOneMedicinesIGmbH,Aeschengraben27,4051Basel,Switzerland","registeredCapital":"15万元","survey":" 百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。","listedPrice":192.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百济神州,688235,百济神州股票,百济神州股票老虎,百济神州股票老虎国际,百济神州行情,百济神州股票行情,百济神州股价,百济神州股市,百济神州股票价格,百济神州股票交易,百济神州股票购买,百济神州股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百济神州(688235)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百济神州(688235)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}